Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

- PMLiVE

Eisai launches online breast cancer resource

Website includes information on the disease, treatment options and side effects

- PMLiVE

Eisai wins US approval for chemotherapy side effects drug

FDA backs Akynzeo to treat nausea and vomiting

- PMLiVE

US clamps down on tax inversion deals

Will make it harder for companies to dodge taxes overseas

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Second time lucky for Takeda’s obesity drug

FDA approves Contrave three years after initial rejection

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

German cost-effectiveness body once again says Fycompa should not be reimbursed

- PMLiVE

US talks tough on ‘unpatriotic’ tax inversion deals

Treasury looks to 'meaningfully reduce' tax benefits of such manoeuvres

- PMLiVE

Eisai names new US financial head

Barry Lederman joins as chief financial officer

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links